A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
European Journal of Cancer2022Vol. 181, pp. 135–144
Citations Over TimeTop 10% of 2022 papers
Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi, Akihiro Ohba, Hiroshi Imaoka, Takeshi Terashima, Hiroshi Ishii, Junki Mizusawa, Hiroshi Katayama, Tomoko Kataoka, Takuji Okusaka, Masafumi Ikeda, Naoki Sasahira, Haruo Miwa, Eishiro Mizukoshi, Naohiro Okano, Nobumasa Mizuno, Tomohisa Yamamoto, Yoshito Komatsu, Akiko Todaka, Ken Kamata, Masayuki Furukawa, Nao Fujimori, Akio Katanuma, Yukiko Takayama, Hidetaka Tsumura, Haruhiko Fukuda, Makoto Ueno, Junji Furuse
Abstract
GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy.
Related Papers
- → FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study(2021)9 cited
- → Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer(2002)18 cited
- → FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)(2022)2 cited
- [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].(2019)
- → The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients(2005)3 cited